Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionValues First Advisors, Inc.
Latest Disclosed Ownership3,246 shares
Latest Disclosed Value $ 1,073,921
Values First Advisors, Inc. reports 0.62% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On April 17, 2026 - Values First Advisors, Inc. filed a 13F-HR form disclosing ownership of 3,246 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $927,382 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 30, 2026 disclosing 3,226 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 0.62% during the quarter. The current value of the position is $817,343 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-17 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,246 20 0.62 1,074 -16.30 0.1930
2026-01-30 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,226 -656 -16.90 1,283 -27.57 0.6655
2025-10-21 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,882 -65 -1.65 1,770 37.53 0.9473
2025-07-29 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,947 -4,166 -51.35 1,287 -41.21 0.7011
2025-04-30 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,113 -879 -9.78 2,189 3.50 1.2769
2025-01-29 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,992 202 2.30 2,116 -12.49 1.1647
2024-10-23 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,790 1,200 15.81 2,417 31.07 1.3111
2024-07-19 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,590 -148 -1.91 1,844 59.52 1.1050
2024-04-23 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,738 755 10.81 1,156 -13.47 0.6778
2024-01-18 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,983 476 7.32 1,337 15.97 0.8065
2023-11-08 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,507 -50 -0.76 1,152 -7.47 0.7445
2023-08-02 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,557 146 2.28 1,245 -3.04 0.7518
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,411 109 1.73 1,284 -14.23 0.8179
2023-01-20 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,302 35 0.56 1,498 19.38 1.0451
2022-12-02 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,267 201 3.31 1,254 41.69 0.9011
2022-07-20 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,066 -430 -6.62 885 -16.59 0.6287
2022-05-03 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,496 347 5.64 1,061 1.73 0.6698
2022-03-10 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,149 -368 -5.65 1,043 -15.20 0.6176
2022-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,517 213 3.38 1,230 15.06 0.7969
2022-11-15 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,304 -130 -2.02 1,069 17.73 0.7251
2022-11-15 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,434 99 1.56 908 10.33 0.6703
2022-11-15 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,335 -199 -3.05 823 -13.46 0.6559
2022-11-15 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,534 331 5.34 951 3.48 0.8740
2022-11-15 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,203 -146 -2.30 919 -99.87 0.9099
2023-01-09 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,349 367 6.14 691,078 100,201.60 0.8296
2022-11-15 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,982 5,982 689 0.6651
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.